Nanologica

Nanologica's mission is to make diabetes and obesity medicines available to more patients by providing products that lower manufacturing costs. The company has achieved this through its proprietary NLAB Saga® silica platform, which offers superior performance in preparative chromatography for peptide purification, and has established itself as a public company on Nasdaq Stockholm. Its strategy combines direct sales of its consumables with CDMO services via Syntagon to capture value across the pharmaceutical manufacturing value chain.

Proprietary NLAB Saga® silica material: a perfectly spherical, fully porous silica with superior mechanical and chemical stability designed for high-performance preparative chromatography, specifically optimized for the purification of peptide drugs.

Competes against large chromatography media giants (Cytiva, Merck, Agilent) and specialized CDMOs. Differentiation is based on the specialized performance of NLAB Saga® for peptide purification and Syntagon's deep expertise in complex molecule purification and analysis, rather than scale.